Verona Pharma (VRP)

 

Latest News

Verona Pharma plc : Block listing Interim Review

Verona Pharma plc: Block listing Interim Review LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on its block listing, pursuant to ...

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, bought 10,000 shares in the company on the 29th November 2017 at a price of 106.85p. The...

Verona Pharma plc : PDMR Dealing

Verona Pharma plc: PDMR Dealing LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive...

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and set its price target at 327p.

All News

DateHeadlineSource
30-11-17Verona Pharma plc : Block listing Interim ReviewRNS
30-11-17Director Deals - Verona Pharma PLC (VRP)StockMarketWire
30-11-17Verona Pharma plc : PDMR DealingRNS
27-11-17Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLCStockMarketWire
07-11-17Verona Pharma losses deepenStockMarketWire
07-11-17Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
07-11-17Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
31-10-17Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
31-10-17Verona Pharma to Present at Two Upcoming Investor ConferencesRNS
02-10-17Verona Pharma plc : Total voting rightsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
27-09-17Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to PatientsRNS
19-09-17Verona to issue sharesStockMarketWire
19-09-17Verona Pharma plc : MiscellaneousRNS
07-09-17Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)RNS
01-09-17Verona Pharma Appoints Stifel as Nominated AdviserRNS
21-08-17Director Deals - Verona Pharma PLC (VRP)StockMarketWire
21-08-17PDMR DealingRNS
08-08-17Verona Pharma losses widen as it starts clinical trialsStockMarketWire
08-08-17Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development UpdateRNS
02-08-17Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development UpdateRNS
01-08-17Verona to present at healthcare conferenceStockMarketWire
01-08-17Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare ConferenceRNS
26-07-17Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
27-06-17Verona nears Phase 2b clinical trial for RPL554StockMarketWire
27-06-17Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeRNS
22-06-17Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory AffairsRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
05-06-17Verona initiates US clinical pharmacokinetic study for RPL554StockMarketWire
05-06-17Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDARNS
30-05-17Holding(s) in CompanyRNS
30-05-17Holding(s) in CompanyRNS
25-05-17Holding(s) in CompanyRNS
25-05-17Verona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting RightsRNS
23-05-17Verona CEO to present at Jefferies Healthcare ConferenceStockMarketWire
23-05-17Verona Pharma to Present at Jefferies 2017 Global Healthcare ConferenceRNS
23-05-17Holding(s) in CompanyRNS
22-05-17Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLCStockMarketWire
16-05-17Partial Exercise of Over-Allotment OptionRNS

RSS feeds

  • Editorial news feed for LSE:VRP Editorial
  • Regulatory news feed for LSE:VRP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account